tirzepatide cvs CVS to cover Zepbound again, expanding access to GLP-1 drug

Eli Lilly cuts price for weight-loss drug Zepbound

23.74

★★★★☆4.8 (126)

CVS Caremark drops Zepbound coverage for Wegovy for weight loss – WSB-TV Channel 2

21.36

★★★★★4.9 (98)

A major shift is unfolding in the obesity treatment landscape as CVS Health announced expanded coverage for Zepbound while also adding @Eli Lilly and Company 's new direct to consumer platform, Foundayo,

23.41

★★★★★5.0 (157)

CVS Health will remove #Zepbound from its preferred formulary starting July 1, 2025, favoring #Wegovy instead. This decision impacts patient access to weight-loss medications, despite Zepbound showing superior results in the SURMOUNT-5

20.04

★★★★★4.7 (84)

CVS Caremark stopped covering a GLP-1 for obesity. Now there's a lawsuit

27.43

★★★★★4.9 (203)

CVS Health announced it will remove Zepbound (tirzepatide) from its preferred formulary list starting July 1, 2025, opting instead to prioritize Wegovy (semaglutide). This formulary change reflects broader negotiations between pharmaceutical companies

23.71

★★★★★5.0 (176)

CVS will begin covering Eli Lilly's newly approved Foundayo pill starting June 1 and restore coverage of Zepbound on Oct. 1, expanding access to the GLP-1 drugs. More at https://fintwit.ai/?utm_source=social&utm_medium=fb_linkedin&utm_campaign

20.57

★★★★★4.8 (132)